Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 8/20 | 0.36 |
| ▸ | ADRB1 | P08588 | 7/20 | 0.36 |
| ▸ | RARA | P10276 | 1/20 | 0.36 |
| ▸ | RARB | P10826 | 1/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.33 |
| ▸ | FAAH | O00519 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.31 |
| ▸ | PPARD | Q03181 | 2/20 | 0.31 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12822310 | 0.96 | ADRB3 (0.37) | ADRB3ADRB1RARARARBS1PR1 | |
| SCHEMBL12719421 | 0.94 | ADRB1 (0.34) | ADRB3ADRB1FAAHL3MBTL1 | |
| SCHEMBL12822511 | 0.94 | ADRB1 (0.34) | ADRB3ADRB1FAAHL3MBTL1 | |
| SCHEMBL12821512 | 0.90 | ADRB1 (0.34) | ADRB3ADRB1 | |
| SCHEMBL12823898 | 0.90 | ADRB1 (0.34) | ADRB3ADRB1 | |
| SCHEMBL12823214 | 0.90 | MAPT (0.39) | ADRB3ADRB1RARARARBFAAH | |
| SCHEMBL12719403 | 0.90 | ALDH1A1 (0.35) | ADRB3ADRB1S1PR1FAAHMAPT | |
| SCHEMBL12822977 | 0.90 | FFAR1 (0.36) | ADRB3ADRB1RARARARBS1PR1 | |
| SCHEMBL14766395 | 0.89 | RARB (0.46) | ADRB3ADRB1RARARARBS1PR1 | |
| SCHEMBL12823956 | 0.88 | ALDH1A1 (0.35) | ADRB3ADRB1S1PR1FAAHMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110090450-A1 | FOUR-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2011-04-21 | — | — | US | disclosed |
| WO-2009150966-A1 | TETRACYCLIC LIQUID CRYSTALLINE COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY ELEMENT | チッソ株式会社 (JP) | 2009-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110090450-A1 | FOUR-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | LEF1, LAS1L, EFHD2 | ADRB3 1116/4885ADRB1 906/4885RARA 2089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.